ENA-78 Is a Novel Predictor of Wound Healing in Patients with Diabetic Foot Ulcers
Table 1
Clinical characteristics of the participants under investigation.
Characteristics
Discovery cohort
Validation cohort 1
Validation cohort 2
RH
NH
RH
NH
RH
12
12
49
36
30
Sex, women (%)
50
58.3
0.256‡
44.9
50
0.479‡
43.3
0.589‡
Age (years)
61.42 (50.50–72.25)
0.446†
0.040
30.10 (11.25–55.25)
0.000 †
BMI (kg/m2)
0.877
0.224
0.241
FPG (mmol/L)
10.27 (6.52–14.22)
9.99 (6.08–10.32)
0.917†
11.09 (6.73–16.49)
14.38 (10.51–17.33)
0.012 †
0.000 †
Ulcer area (cm2)
3.03 (1.23–3.10)
2.78 (1.85–3.10)
0.788†
2.91 (1.60–2.55)
2.77 (1.30–2.60)
0.820†
0.000 †
HbA1C (%)
8.78 (6.63–12.03)
0.313†
0.000
/
/
Diabetes duration (years)
0.629
8.54 (2.75–12.00)
8.31 (4.63–11.38)
0.869†
/
/
Hypertension (%)
50
50
1.000‡
32
18
0.157‡
/
/
Hyperlipidemia (%)
16.7
8.3
0.054‡
11
7
0.738‡
/
/
Antibiotic therapy (%)
41.7
41.7
1.000‡
18
19
0.140‡
/
/
FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin. Data are shown as mean ± SEM, median (interquartile range), or percentage (%) of subjects in each group. Significant values are marked in italic. Differences between the groups (RH vs NH) were analyzed using †Mann-Whitney U test or ‡ test; all the others were analyzed using t-tests. In validation cohort 2 group, was compared with NH (validation cohort 1).
